Bulletin
Investor Alert

New York Markets Open in:

Market Pulse Archives

May 19, 2022, 8:25 a.m. EDT

Indaptus shares jump after announcing plans to test cancer treatment in a Phase 1 clinical trial

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Indaptus Therapeutics Inc. (INDP)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Indaptus Therapeutics Inc. /zigman2/quotes/204811863/composite INDP -0.49% were up 21.6% in premarket trading on Thursday after the company said U.S. regulators have allowed a Phase 1 clinical trial for its experimental cancer treatment to move forward. Indaptus plans to enroll patients with advanced solid tumors who have already unsucessfully undergone approved treatments. The study is set to begin in the second half of the year. Indaptus stock has tumbled 56.1% this year, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +3.06% has declined 17.7%.

/zigman2/quotes/204811863/composite
US : U.S.: Nasdaq
$ 2.03
-0.01 -0.49%
Volume: 36,337
June 24, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$16.76 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,911.74
+116.01 +3.06%
Volume: 3.46B
June 24, 2022 5:05p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.